Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study

1999 ◽  
Vol 99 (1) ◽  
pp. 51-58 ◽  
Author(s):  
V. Caillard ◽  
F. Rouillon ◽  
J. F. Viel ◽  
S. Markabi
Keyword(s):  
Panic Disorder ◽  
Controlled Study ◽  
Double Blind ◽  
High Doses

Anxiogenic effects of Sumatriptan in panic disorder: A double-blind, placebo-controlled study

2005 ◽  
Vol 15 (3) ◽  
pp. 279-282 ◽  
Author(s):  
Daniella Amital ◽  
Leah Fostick ◽  
Yehuda Sasson ◽  
Seth Kindler ◽  
Howard Amital ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study

1995 ◽  
Vol 167 (3) ◽  
pp. 374-379 ◽  
Author(s):  
S. Oehrberg ◽  
P. E. Christiansen ◽  
K. Behnke ◽  
A. L. Borup ◽  
B. Severin ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Cognitive Therapy ◽  
Panic Attacks ◽  
Controlled Study ◽  
Positive Trend ◽  
Double Blind ◽  
Treatment Groups ◽  
Efficacy Measures ◽  
The Mean ◽  
Primary Measure

BackgroundThis study compared the efficacy and tolerability of paroxetine with placebo in the treatment of panic disorder.MethodAfter three weeks of placebo, patients received 12 weeks of treatment with paroxetine (20, 40, or 60 mg) or placebo, and finally two weeks of placebo. Dosages were adjusted according to efficacy and tolerability. Standardised cognitive therapy was given to all patients. The primary measure of outcome was reduction in the number of panic attacks.ResultsAnalysis of the results showed statistically significant differences in favour of paroxetine between the two treatment groups in two out of the three primary measures of outcome, i.e. 50% reduction in total number of panic attacks and number of panic attacks reduced to one or zero over the study period. For the third measure of outcome, the mean change in the total number of attacks from baseline, there was a positive trend in favour of paroxetine. The results of the primary measures of outcome were strongly supported by the results of the secondary efficacy measures of outcome. In addition, paroxetine, at all doses, was very well tolerated.ConclusionParoxetine plus cognitive therapy was significantly more effective than placebo plus cognitive therapy in the treatment of panic disorder.

A Controlled Study of Cognitive Behaviour Therapy with Buspirone or Placebo in Panic Disorder with Agoraphobia

1995 ◽  
Vol 167 (5) ◽  
pp. 635-641 ◽  
Author(s):  
Jean Cottraux ◽  
Ivan-Druon Note ◽  
Charly Cungi ◽  
Patrick Légeron ◽  
François Heim ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Multicentre Study ◽  
Cognitive Behaviour Therapy ◽  
Group Analysis ◽  
Panic Attacks ◽  
Controlled Study ◽  
Behaviour Therapy ◽  
Short Term ◽  
Double Blind ◽  
Cognitive Behaviour

BackgroundThis multicentre study compared a 16-week buspirone treatment with placebo in patients presenting with panic disorder with agoraphobia and also receiving cognitive behaviour therapy (CBT).MethodDouble-blind testing was maintained until week 68, but not tested; 91 patients were included; 14 placebo-responders excluded; 77 patients randomised; 48 reached week 16 and 41 reached week 68.ResultsAt week 16, within-group analysis showed significant improvements in agoraphobia, panic attacks, and depression in both groups. Generalised anxiety improved only in CBT + buspirone. Between-group comparisons showed buspirone to have an effect on generalised anxiety and agoraphobia. Changes in degree of agoraphobia and depression were correlated in subjects on CBT + buspirone only. A significantly higher proportion of women, and of subjects showing high avoidance dropped out. Positive expectations regarding medication predicted success in both groups. At week 68, improvement was retained without significant buspirone effect.ConclusionBuspirone enhanced the effects of cognitive behaviour therapy on generalised anxiety and agoraphobia in the short term.

Effect of Fish Oil on Appetite and Other Symptoms in Patients With Advanced Cancer and Anorexia/Cachexia: A Double-Blind, Placebo-Controlled Study

2003 ◽  
Vol 21 (1) ◽  
pp. 129-134 ◽  
Author(s):  
Eduardo Bruera ◽  
Florian Strasser ◽  
J. Lynn Palmer ◽  
Jie Willey ◽  
Kathryn Calder ◽  
...  
Keyword(s):  
Nutritional Status ◽  
Fish Oil ◽  
Advanced Cancer ◽  
Caloric Intake ◽  
Well Being ◽  
Controlled Study ◽  
Double Blind ◽  
Baseline Weight ◽  
High Doses ◽  
And Function

Purpose: To determine whether high doses of fish oil, administered over 2 weeks, improve symptoms in patients with advanced cancer and decreased weight and appetite. Patients and Methods: Sixty patients were randomly assigned to fish oil capsules or placebo. Appetite, tiredness, nausea, well-being, caloric intake, nutritional status, and function were prospectively assessed at days 1 and 14. Results: The baseline weight loss was 16 ± 11 and 16 ± 8 kg in the fish oil (n = 30) and placebo (n = 30) group respectively, whereas the baseline appetite (0 mm = best and 10 mm = worst) was 58 ± 24 mm and 67 ± 19 mm, respectively (P = not significant). The mean daily dose was 10 ± 4 (fish oil group) and 9 ± 3 (placebo group) capsules, which provided 1.8 g of eicosapentaenoic acid and 1.2 g of docosahexaenoic acid in the fish oil group. No significant differences in symptomatic or nutritional parameters were found (P < .05), and there was no correlation between changes in different variables between days 1 and 14 and the fish oil doses. Finally, the majority of the patients were not able to swallow more than 10 fish oil capsules per day, mainly because of burping and aftertaste. Conclusion: Fish oil did not significantly influence appetite, tiredness, nausea, well-being, caloric intake, nutritional status, or function after 2 weeks compared with placebo in patients with advanced cancer and loss of both weight and appetite.

Propranolol in Chronic Schizophrenia: A Controlled Study in Neuroleptic-Treated Patients

1980 ◽  
Vol 137 (2) ◽  
pp. 126-130 ◽  
Author(s):  
Leif H. Lindström ◽  
Eva Persson
Keyword(s):  
Rating Scale ◽  
Chronic Schizophrenia ◽  
Placebo Treatment ◽  
Controlled Study ◽  
Psychotic Symptoms ◽  
Double Blind ◽  
Schizophrenic Patients ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale ◽  
High Doses

The effect of propranolol at a dose level of 1,280–1,920 mg per day was studied with a double-blind crossover design in twelve chronic schizophrenics with persistent psychotic symptoms despite maintenance treatment with a depot neuroleptic. By use of a psychiatric rating scale (CPRS), an improvement was seen during the two week period of propranolol compared to placebo treatment in six patients, whereas three patients were unchanged and three deteriorated. The effect on total symptom scores for the whole group was significantly better after propranolol. The data indicate that propranolol in high doses has an antipsychotic effect in some schizophrenic patients when receiving neuroleptics.

High Doses of Inhaled Corticosteroids in Unstable Chronic Asthma: A Multicenter, Double-blind, Placebo-controlled Study

1989 ◽  
Vol 140 (1) ◽  
pp. 167-171 ◽  
Author(s):  
Sergio Salmeron ◽  
Jean-Claude Guerin ◽  
Philippe Godard ◽  
Dominique Renon ◽  
Michel Henry-Amar ◽  
...  
Keyword(s):  
Inhaled Corticosteroids ◽  
Controlled Study ◽  
Chronic Asthma ◽  
Double Blind ◽  
Double Blind Placebo ◽  
High Doses

Effects of Hypericum Extract on the Sleep EEG in Older Volunteers

1994 ◽  
Vol 7 (1_suppl) ◽  
pp. 39-43 ◽  
Author(s):  
H. Schulz ◽  
M. Jobert
Keyword(s):  
Tricyclic Antidepressants ◽  
Visual Analysis ◽  
Well Being ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Older Volunteers ◽  
Washout Phase ◽  
High Doses ◽  
Hypericum Extract

The effects of treatment with high doses (300 mg three times daily) of hypericum extract LI 160 on sleep quality and well-being were investigated over a 4-week period. The double-blind, placebo-controlled study was conducted with 12 older, healthy volunteers in a cross-over design, which included a 2-week washout phase between both treatment phases. A hypostatic influence of the REM sleep phases, which is typical for tricyclic antidepressants and MAO inhibitors, could not be shown for this phytopharmacon. Instead, LI 160 induced an increase of deep sleeP during the total sleeping period. This could be shown consistently in the visual analysis of the sleeping phases 3 and 4, as well as in the automatic analysis of slow-wave EEG activities. The continuity of sleep was not improved by LI 160; this was also the case for the onset of the sleep, the intermittent wake-up phases, and total sleep duration.

Sign in / Sign up

Export Citation Format

Share Document